Recursion Q2 2025: $7M Sanofi milestone; REC-1245 and REC-617 trial updates

RECURSION PHARMACEUTICALS, INC.

2025-Q2 EPS reported -$0.91 revenue$33,968,000

Announced $7 million milestone from Sanofi partnership for partnered discovery program.
REC-1245 (RBM39) DAHLIA Phase 1/2 trial enrolling patients with tumors exhibiting replication stress and DDR vulnerabilities.
REC-617 (CDK7 inhibitor) combination cohort to target platinum-resistant ovarian cancer using multi-omic and causal AI.
Co-founder and CEO Chris Gibson highlighted platform advancements including Boltz-2 for ligand design.
Exhibit text truncated; specific Q2 revenue, EPS, and cash position figures were not provided in the available excerpt.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.